A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Financial Summary
| Share Statistics | AIDX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4.9 | $389.6 | 3% |
|
| Shares Out (Mil) | 10.8 | 40.9 | 22% |
|
| Institutional Ownership | 54.3% | 82.8% | 37% |
|
| Float (Mil) | 10.8 | 35.5 | 20% |
|
| Beta | na | 0.85 | na |
|
| Avg Daily Volume (000s) | 62 | 298 | 30% |
|
| Price Change (52-week) |
na | 63.7% | na |
|
| Growth | AIDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 46.1% | 11.8% | 95% |
|
| Net Income (5yr) | (19.8%) | (5.6%) | 20% |
|
| EPS (5yr) | (19.6%) | 10.2% | 14 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.3%) | (15.5%) | 37% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AIDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $141 | 3% |
|
| Net Income (TTM) (Mil) | ($6) | ($9) | 33% |
|
| EPS (TTM) | ($0.997) | ($0.400) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($2) | 28% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $26 | 14% |
|
| Enterprise Value (Q1) (Mil) | $5 | $409 | 5% |
|
| Valuation | AIDX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.92 | 2.73 | 66% |
|
| P/E | na | 25.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | AIDX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 31.5% | 58.7% | 37% |
|
| Net Margin | (285.0%) | (6.9%) | 3% |
|
| ROA | (131.8%) | (12.2%) | 4% |
|
| ROE | (604.1%) | (10.7%) | 1% |
|
| Liabilities to Assets | 48.4% | 47.2% | 40% |
|
| F-Score | 3 | 4 | 18% |
|
20/20 Biolabs, Inc. did not pass any screens on 10/2/2026.
